Fifteen-year Trends and Differences in Mortality Rates Across Sex, Age, and Race/ethnicity in Patients with Brainstem Tumors

Overview

Journal Neurooncol Adv

Publisher Oxford University Press

Date 2021 Oct 25

PMID 34693287

Citations 2

Authors

Yusuke Tomita

Yoshihiro Tanaka

Nozomu Takata

Elizabeth A Hibler

Rintaro Hashizume

Oren Josh Becher

Affiliations

Soon will be listed here.

Abstract

Background: Localization of tumors to the brainstem carries a poor prognosis, however, risk factors are poorly understood. We examined secular trends in mortality from brainstem tumors in the United States by age, sex, and race/ethnicity.

Methods: We extracted age-adjusted incidence-based mortality rates of brainstem tumors from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2018. Trends in age-adjusted mortality rate (AAMR) were compared by sex and race/ethnicity among the younger age group (0-14 years) and the older age group (>15 years), respectively. Average AAMRs in each 5-year age group were compared by sex.

Results: This study included 2039 brainstem tumor-related deaths between 2004 and 2018. Trends in AAMRs were constant during the study period in both age groups, with 3 times higher AAMR in the younger age group compared to the older age group. Males had a significantly higher AAMR in the older age group, while no racial differences were observed. Intriguingly, AAMRs peaked in patients 5-9 years of age (0.57 per 100 000) and in patients 80-84 years of age (0.31 per 100 000), with lower rates among middle-aged individuals. Among 5-9 years of age, the average AAMR for females was significantly higher than that of males ( = .017), whereas the reverse trend was seen among those 50-79 years of age.

Conclusions: Overall trends in AAMRs for brainstem tumors were constant during the study period with significant differences by age and sex. Identifying the biological mechanisms of demographic differences in AAMR may help understand this fatal pathology.

Citing Articles

The Next Frontier in Health Disparities-A Closer Look at Exploring Sex Differences in Glioma Data and Omics Analysis, from Bench to Bedside and Back.

Diaz Rosario M, Kaur H, Tasci E, Shankavaram U, Sproull M, Zhuge Y Biomolecules. 2022; 12(9).

PMID: 36139042 PMC: 9496358. DOI: 10.3390/biom12091203.

Age is a major determinant for poor prognosis in patients with pilocytic astrocytoma: a SEER population study.

Tomita Y, Hibler E, Suruga Y, Ishida J, Fujii K, Satomi K Clin Exp Med. 2022; 23(6):2301-2309.

PMID: 36063258 DOI: 10.1007/s10238-022-00882-5.

References

Reyes-Botero G, Mokhtari K, Martin-Duverneuil N, Delattre J, Laigle-Donadey F . Adult brainstem gliomas. Oncologist. 2012; 17(3):388-97. PMC: 3316925. DOI: 10.1634/theoncologist.2011-0335. View

Ostrom Q, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C . CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 2017; 19(suppl_5):v1-v88. PMC: 5693142. DOI: 10.1093/neuonc/nox158. View

Katagi H, Takata N, Aoi Y, Zhang Y, Rendleman E, Blyth G . Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma. Neuro Oncol. 2021; 23(8):1348-1359. PMC: 8328031. DOI: 10.1093/neuonc/noab009. View

Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M . Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet. 2014; 46(5):451-6. PMC: 3997489. DOI: 10.1038/ng.2936. View

Zhang Q, Wang Y, Hu H, Huang R, Xie L, Liu E . Impact of socioeconomic status on survival of colorectal cancer patients. Oncotarget. 2017; 8(62):106121-106131. PMC: 5739706. DOI: 10.18632/oncotarget.20859. View

Clegg L, Reichman M, Hankey B, Miller B, Lin Y, Johnson N . Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies. Cancer Causes Control. 2007; 18(2):177-87. DOI: 10.1007/s10552-006-0089-4. View

Clegg L, Hankey B, Tiwari R, Feuer E, Edwards B . Estimating average annual per cent change in trend analysis. Stat Med. 2009; 28(29):3670-82. PMC: 2843083. DOI: 10.1002/sim.3733. View

Haifler M, Neheman A, Zisman A . Has Stage Migration in Renal Cancer Run Its Course? A SEER Database Analysis. Clin Genitourin Cancer. 2020; 18(4):e368-e373. DOI: 10.1016/j.clgc.2020.01.005. View

Maxwell R, Luksik A, Garzon-Muvdi T, Yang W, Huang J, Bettegowda C . Population-based Study Determining Predictors of Cancer-Specific Mortality and Survival in Pediatric High-grade Brainstem Glioma. World Neurosurg. 2018; 119:e1006-e1015. DOI: 10.1016/j.wneu.2018.08.044. View

10.

Chu K, Miller B, Feuer E, Hankey B . A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer. J Clin Epidemiol. 1994; 47(12):1451-61. DOI: 10.1016/0895-4356(94)90089-2. View

11.

Patil N, Kelly M, Yeboa D, Buerki R, Cioffi G, Balaji S . Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017. Neuro Oncol. 2020; 23(6):990-998. PMC: 8168816. DOI: 10.1093/neuonc/noaa295. View

12.

Taylor K, Mackay A, Truffaux N, Butterfield Y, Morozova O, Philippe C . Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet. 2014; 46(5):457-461. PMC: 4018681. DOI: 10.1038/ng.2925. View

13.

Reithmeier T, Kuzeawu A, Hentschel B, Loeffler M, Trippel M, Nikkhah G . Retrospective analysis of 104 histologically proven adult brainstem gliomas: clinical symptoms, therapeutic approaches and prognostic factors. BMC Cancer. 2014; 14:115. PMC: 3975961. DOI: 10.1186/1471-2407-14-115. View

14.

Katagi H, Louis N, Unruh D, Sasaki T, He X, Zhang A . Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma. Clin Cancer Res. 2019; 25(18):5572-5583. PMC: 6744979. DOI: 10.1158/1078-0432.CCR-18-3890. View

15.

Fonseca A, Afzal S, Bowes L, Crooks B, Larouche V, Jabado N . Pontine gliomas a 10-year population-based study: a report from The Canadian Paediatric Brain Tumour Consortium (CPBTC). J Neurooncol. 2020; 149(1):45-54. DOI: 10.1007/s11060-020-03568-8. View

16.

Souweidane M, Kramer K, Pandit-Taskar N, Zhou Z, Haque S, Zanzonico P . Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol. 2018; 19(8):1040-1050. PMC: 6692905. DOI: 10.1016/S1470-2045(18)30322-X. View

17.

Ostrom Q, Cote D, Ascha M, Kruchko C, Barnholtz-Sloan J . Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014. JAMA Oncol. 2018; 4(9):1254-1262. PMC: 6143018. DOI: 10.1001/jamaoncol.2018.1789. View

18.

Chen L, Pan C, Diplas B, Xu C, Hansen L, Wu Y . The integrated genomic and epigenomic landscape of brainstem glioma. Nat Commun. 2020; 11(1):3077. PMC: 7299931. DOI: 10.1038/s41467-020-16682-y. View

19.

Ostrom Q, Krebs H, Patil N, Cioffi G, Barnholtz-Sloan J . Racial/ethnic disparities in treatment pattern and time to treatment for adults with glioblastoma in the US. J Neurooncol. 2021; 152(3):603-615. DOI: 10.1007/s11060-021-03736-4. View

20.

Ostrom Q, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol. 2019; 21(Suppl 5):v1-v100. PMC: 6823730. DOI: 10.1093/neuonc/noz150. View